Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 9963515

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963700

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963699

Methods for modulating C9ORF72 expression

The Regents of the University of California · Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957292

Compositions and methods for modulating angiopoietin-like 3 expression

Ionis Pharmaceuticals, Inc. · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957501

Nuclease-mediated regulation of gene expression

Sangamo Therapeutics, Inc. · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957504

Compositions and methods for modulating apolipoprotein (a) expression

Ionis Pharmaceuticals, Inc. · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957507

Compositions and methods for inhibiting expression of mutant EGFR gene

Alnylam Pharmaceuticals, Inc. · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957569

Recurrent gene fusions in prostate cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9950010

Genetically-modified cells comprising a modified human T cell receptor alpha constant regi

Precision BioSciences, Inc. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9950011

Genetically-modified cells comprising a modified human T cell receptor alpha constant regi

Precision BioSciences, Inc. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9944926

Induced exon inclusion in spinal muscle atrophy

Sarepta Therapeutics, Inc. · Granted Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938531

Compositions and methods for inhibiting expression of RRM2 genes

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938582

Recurrent gene fusions in prostate cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938353

Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

The Regents of the University of Colorado, a Body Corporate · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938344

Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colo

PRECISION BIOLOGICS, INC. · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932589

EML4-ALK fusion gene

CUREGENE K.K. · Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932593

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932581

Compositions and methods for modulating apolipoprotein C-III expression

Ionis Pharmaceuticals, Inc. · Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932580

Compositions and methods for modulating HBV expression

Ionis Pharmaceuticals, Inc. · Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9926602

Recurrent gene fusions in prostate cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9920109

Serpin fusion polypeptides and methods of purification thereof

Inhibrx, Inc. · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914765

WAP domain fusion polypeptides and methods of use thereof

Inhibrx, Inc. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914927

RNAi inhibition of alpha-ENaC expression

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9909124

Compounds and methods for modulating apolipoprotein C-III expression for improving a diabe

Ionis Pharmaceuticals, Inc. · Granted Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted